Kymera prices $250.8M public offering of common stock and pre-funded warrants

Kymera Therapeutics, Inc.

Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.
Net proceeds estimated at $237.3M (or $272.7M if underwriters option for 855K shares exercised).
Proceeds to advance preclinical/clinical degrader programs and for working capital.
Existing cash plus offering proceeds expected to fund operations into mid 2028.
Company also entered registration rights agreement with Baker, Atlas, and BVF affiliates for up to 27.96M resale shares.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.